1. Zost, S.J.; Parkhouse, K.; Gumina, M.E.; Kim, K.; Diaz Perez, S.; Wilson, P.C.; Treanor, J.J.; Sant, A.J.; Cobey, S.; Hensley, S.E. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccinestrains. Proc. Natl. Acad. Sci. USA 2017, 114, 12578–12583.

2. de Lejarazu-Leonardo OR, Montomoli E, Wojcik R, Christopher S, Mosnier A, Pariani E, Trilla Garcia A, Fickenscher H, Gärtner BC, Jandhyala R, et al. Estimation of reduction in influenza vaccine effectiveness due to egg-adaptation changes—Systematic literature review and expert consensus. Vaccines. 2021;9(11):1255.

3. Coleman B.L, Gutmanis I, McGovern I, Haag M. Effectiveness of Cell-Based uadrivalent Seasonal Influenza Vaccine: A Systematic Review and Meta-Analysis. Vaccines. 2023, 11, 1607

4. Boikos C, McGovern I, Molrine D, Ortiz JR, Puig-Barberà J, Haag M. Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons. Vaccines. 2022; 10(10):896.

5. Boikos C, Fischer L, O’Brien D, Vasey J, Sylvester GC, Mansi JA. Relative effectiveness of the cell-derived inactivated quadrivalent influenza vaccine versus egg-derived inactivated quadrivalent influenza vaccines in preventing influenza-related medical encounters during the 2018-2019 influenza season in the United States. Clin Infect Dis. 2021;73:e692–e698

6. Boikos C, Sylvester GC, Sampalis JS, Mansi JA 2020. Relative Effectiveness of the Cell-Cultured Quadrivalent Influenza Vaccine Compared to Standard, Egg-derived Quadrivalent Influenza Vaccines in Preventing Influenza-like Illness in 2017-2018. Clinical Infectious Diseases. 2020;71(10):e665-71

7. Divino V, Krishnarajah G, Pelton SI, Mould-Quevedo J, Anupindi V, DeKoven M, Postma MJ. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-2018 influenza season. Vaccine. 2020;38;6334-6343

8. Krishnarajah G, Divino V, Postma MJ, Pelton SI, Anupindi VR, DeKoven M, Mould-Quevedo J. Clinical and economic outcomes associated with cell-based quadrivalent influenza vaccine vs. standard-dose egg-based quadrivalent influenza vaccines during the 2018–2019 influenza season in the United States. Vaccines. 2021;9:80.

9.Ku JH, Rayens E, Sy LS, et al. Comparative effectiveness of licensed influenza vaccines in preventing influenza-related medical encounters and hospitalizations in the 2022-2023 influenza season among adults >/=65 years of age. Clin Infect Dis. 2024;79(5):1283-92. doi: 10.1093/cid/ciae375

10. Nolan T, Chotpitayasunondh T, Capeding MR, et al. Safety and tolerability of a cell culture derived trivalent subunit inactivated influenza vaccine administered to healthy children and adolescents: A Phase III, randomized, multicenter, observer-blind study. Vaccine 2016;34:230-6.

11.Sigma-Aldrich. Egg-based and Cell-based Influenza Vaccine Manufacturing Methods. 2024. Available at: https://www.sigmaaldrich.com/NZ/en/technical-documents/technical-article/pharmaceutical-and-biopharmaceutical-manufacturing/vaccine-manufacturing/egg-based-cell-based-influenza-vaccine-manufacturing

12. Ambrozaitis A, Groth N, Bugarini R, et al. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine. Vaccine 2009;27:6022–9.

13. Hughes MM, Reed C, Flannery B, Garg S, Singleton J, Fry A, Rolfes M. Projected Population Benefit of Increased effectiveness and Coverage of Influenza Vaccination on Influenza Vaccination on Influenza Burden – United States. Clin Infect Dis. 2020;70(12):2496-2502

‍